Botfet / Company detail

BCRX

universe

BioCryst Pharmaceuticals, Inc.

biotech

Moat score54out of 100

The numbers

Financial metrics

Quality gate and thesis context

Roic105.2%

Gross Margin97.8%

Revenue Cagr53.6%

Fcf Conversion124.1%

Fcf Yield16.1%

Interest Coverage4.4x

Market Cap B$2.0B

PeNot available: not applicable loss making

Quality PassPass

Founder LedNo

Thesis AlignedYes

Moat Quant54

Why it may endure

Moat breakdown

Quant: 54 · Curator: 0

Market Share Stability6

Network Effects6

Pricing Power20

Regulatory Moat16

Switching Costs6

Conviction0/10

Leadership0/10

Vision0/10

← Back to the full screener